https://scholars.lib.ntu.edu.tw/handle/123456789/487379
標題: | Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma | 作者: | Huang C.-L. ZHONG-ZHE LIN Su I.-J. Chao T.-Y. HWEI-FANG TIEN Chang M.-C. Huang M.-C. Kao W.-Y. JIH-LUH TANG KUN-HUEI YEH Wang C.-H. CHIH-HUNG HSU Liu M.-Y. ANN-LII CHENG |
公開日期: | 2002 | 出版社: | Taylor and Francis Ltd. | 卷: | 43 | 期: | 7 | 起(迄)頁: | 1415-1420 | 來源出版物: | Leukemia and Lymphoma | 摘要: | We previously reported the therapeutic efficacy of 13-cis retinoic acid (13-cRA) in some subtypes of peripheral T-cell lymphoma (PTCL). This study sought to clarify if the addition of interferon-α2a (IFN-α2a), an agent with synergistic cytotoxicity with 13-cRA in many types of malignant cells, may be more effective in the treatment of PTCL. Eligible patients has histologically proven PTCL, which was recurrent after or refractory to anthracycline-containing systemic chemotherapy. The treatment included oral administration of 13-cRA 1 mg/kg/day, divided into three doses, and intramuscular injection of IFN-α2a 4.5 MU/m2, three times per week. From March 1995 to July 2000, a total of 17 patients, 10 men and 7 women, with a median age of 47 years (range, 18-77 years), were recruited. The histologic diagnosis included 7 cases of unspecified PTCL, 6 cases of Ki-1 anaplastic large cell lymphoma (ALCL), 1 case of angioimmunoblastic T-cell lymphoma, and 3 cases of angiocentric nasal NK/T cell lymphoma. They received a median of 1.7 months of treatment (range, 0.4-13.3 months). One patient refused further treatment due to toxicity. The doses of 13-cRA and IFN-α2a had to be decreased in 7 and 7 patients, respectively. Grade III/IV hematologic and non-hematologic toxicity developed in 2 and 5 patients, respectively. There were 5 partial responses (Ki-1, 4; unspecified PTCL, 1), with a total response rate of 31.3% (95% Cl, 5.7-56.8%). The median duration of response for the responders was 2.5 months (range, 0.8-7.2 months). The median overall survival for the entire group of patients was 3.6 months. In conclusion, a combination of 13-cRA and IFN-α2a is a useful salvage treatment for selected patients with recurrent or refractory PTCL, particularly those with the Ki-1 subtype. However, the data does not support that addition of IFN-α2a is superior to 13-cRA alone. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036299626&doi=10.1080%2f1042819022386806&partnerID=40&md5=286cf377046745980c860ab0c03d8d9d https://scholars.lib.ntu.edu.tw/handle/123456789/487379 |
ISSN: | 1042-8194 | DOI: | 10.1080/1042819022386806 | SDG/關鍵字: | anthracycline; bleomycin; CD30 antigen; cisplatin; cyclophosphamide; cytarabine; dexamethasone; doxorubicin; etoposide; isotretinoin; methotrexate; methylprednisolone; mitoxantrone; prednisone; recombinant alpha2a interferon; vincristine; alpha2a interferon; antineoplastic agent; isotretinoin; adult; aged; article; blood toxicity; cancer cell; cancer combination chemotherapy; cancer survival; cheilitis; clinical article; clinical trial; controlled clinical trial; controlled study; dose response; drug cytotoxicity; drug efficacy; drug potentiation; epistaxis; erythema; eye irritation; female; fever; flu like syndrome; gastrointestinal symptom; headache; histopathology; human; hyperlipidemia; large cell lymphoma; male; multicenter study; myalgia; peripheral lymphocyte; phase 2 clinical trial; priority journal; recurrent cancer; survival time; T cell lymphoma; adolescent; middle aged; mortality; peripheral T cell lymphoma; remission; salvage therapy; survival; survival rate; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Interferon Alfa-2a; Isotretinoin; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。